Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest ...

From mass-producing insulin to building pharmaceutical AI “factories,” Lilly’s 150-year North Star remains the same: being in ...

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

The company still has a strong lead in its core therapeutic area.

Eli Lilly's valuation looks far more attractive now than it did even a year ago.

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...

The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be ...

Eli Lilly and Company (NYSE:LLY) held its 2026 annual meeting of shareholders virtually, with Vice President of ...

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.